

Applicant : M. Amin Arnal  
Serial No. : 09/805,354  
Filed : March 13, 2001  
Page : 4

Attorney's Docket No.: 00786-536001

**REMARKS**


Applicant hereby submits that the enclosures fulfill the requirements under 37 C.F.R. §1.821-1.825. The amendments in the specification merely insert the paper copy of the Sequence Listing and sequence identifiers in the specification. No new matter has been added.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 30 MAY 2002

  
\_\_\_\_\_  
Anita L. Meiklejohn, Ph.D.  
Reg. No. 35,283

Fish & Richardson P.C.  
225 Franklin Street  
Boston, Massachusetts 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

Applicant : M. Amin Arsal.  
 Serial No. : 09/805,354  
 Filed : March 13, 2001  
 Page : 5

Attorney's Docket No.: 00786-536001

### **“Version With Markings to Show Changes Made”**

#### In the specification:

Paragraph beginning at page 7, line 11, has been amended as follows:

Figure 5 depicts an alignment of the A domains of nine alpha integrin  $\alpha$  subunit (CD11b (SEQ ID NO:1), CD11c (SEQ ID NO:2), CD11d (SEQ ID NO:3), CD11a (SEQ ID NO:4), alpha 1 (SEQ ID NO:5), alpha 2 (SEQ ID NO:6), alpha 10 (SEQ ID NO:7), alpha 11 (SEQ ID NO:8), and alpha E (SEQ ID NO:9)). In this alignment, the invariant Ile (I316) is indicated by an arrow.

Paragraph beginning at page 7, line 17, has been amended as follows:

Figure 7 is an alignment of the A-like domains of eight integrin  $\beta$  subunits  $\beta$ 3 (SEQ ID NO:10),  $\beta$ 5 (SEQ ID NO:11),  $\beta$ 6 (SEQ ID NO:12),  $\beta$ 1 (SEQ ID NO:13),  $\beta$ 2 (SEQ ID NO:14),  $\beta$ 7 (SEQ ID NO:15),  $\beta$ 8 (SEQ ID NO:16), and  $\beta$ 9 (SEQ ID NO:17). In this alignment, the residue corresponding to the invariant Ile in  $\beta$  subunits is indicated by an arrow.

Paragraph beginning at page 8, line3, has been amended as follows:

The variant polypeptides were created using standard recombinant techniques. Restriction and modification enzymes were purchased from New England Biolabs, Inc. (Beverly, MA), Boehringer Mannheim (Germany), or GIBCO BRL (Gaithersburg, MD). Site-directed mutagenesis was carried out in pGEX-4T-1 vector as described (Rieu et al. 1996 *J Biol Chem* 271:15858). The following mutagenic primers were used. IFAdel Fwd: 5'-TATAGGATCCGAGGCCCTCCGAGGGAGTCCTCAAGAGGATAG-3' (SEQ ID NO:18); Reverse: 5'-CTACTCGAGTTACTTCTCCCGAAGCTGGTTCTGAATGGTC-3' (SEQ ID NO:19); I-G reverse: 5'-CTACTCGAGTTAACCCTCGATCGCAAAGCCCTTCTC-3' (SEQ ID NO:20). Introduction of the respective mutation was confirmed by direct DNA sequencing. The PvuI-BspEI-restricted cDNA fragment of the A-domain containing the mutation was subcloned into the PvuI-BspEI-restricted CD11b cDNA, cloned into pcDNA3 plasmid, which containing full-length human CD11b (Rieu et al. 1996 *J Biol Chem* 271:15858). 11b A<sup>123-321</sup> and

Applicant : M. Amin Arnal.  
Serial No. : 09/805,354  
Filed : March 13, 2001  
Page : 6

Attorney's Docket No.: 00786-536001

11bA<sup>123-315</sup> and 11bA<sup>1→G</sup> A-domains were expressed as GST fusion proteins in *Escherichia coli* (Michishita et al. 1993 Cell 72:857), cleaved with thrombin and purified as described Li et al. 1999 *J. Cell Biol* 143:1523. C<sup>129</sup> was replaced by S in all the expressed GST-A-domain fusion form to prevent formation of disulfide-linked dimers in solution after thrombin cleavage (not shown). Purity was confirmed by SDS-PAGE analysis.